Susceptibility of Clinical Strains of Herpes simplex Virus to Three Nucleoside Analogues

Abstract

The susceptibility of clinical isolates of herpes simplex virus 1 (HSV1) (58 strains) and 2 (HSV2) (17 strains) from the Centre Hospitalier et Universitaire de Nancy to three nucleoside analogues was compared by the dye uptake method. As expected, all strains of HSV2 were resistant to brovavir or sorivudine. Aciclovir and penciclovir activities were comparable; 2 strains of HSV1 were resistant to these two compounds. Four strains isolated from immunocompromised patients gave different results with brovavir as compared to aciclovir; resistance to aciclovir (1 strain of HSV1) did not correlate with resistance to brovavir (3 strains of HSV1). Following up antiviral susceptibility is of interest for the detection of resistant strains in immunocompromised patients receiving prophylactic aciclovir.

Synergistic in vitro Interactions between (22S,23S)-3β-Bromo-5α,22,23-Trihydroxystigmastan-6-one and Acyclovir or Foscarnet against Herpes simplex Virus Type 1

“…Combined antiviral therapy with two or more drugs has now been shown to be benefi cial in the treatment of several infections [3][4][5] . In this study, we describe the synergistic effects of combinations of a synthetic brassinosteroid derivative with some conventional anti-HSV drugs.…”

“…An ongoing concern in HSV chemotherapy is the development of viral resistance for current available drugs such as acyclovir (ACV) and other nucleoside analogues [1][2][3] . Therefore, it is important that new and novel chemotherapeutics to treat HSV infections are continually developed.…”

Comparison of Efficacy of Oral Valacyclovir and Topical Acyclovir in the Treatment of Herpes Simplex Keratitis: A Randomized Clinical Trial

“…Oral ACV has widely been used in the treatment of herpes simplex keratitis and was reported to have a similar effi cacy to topical ACV ointment therapy [1,4] . Oral ACV has also been shown to be effective in the treatment of disciform herpetic keratitis [5] .…”

Cytomegalovirus Enteritis in an Immunocompetent Host

“…More than 50% of the adult population has acquired CMV antibodies by the fourth decade of life [2]. CMV infection of the gastrointestinal tract is most often seen in patients with the acquired immunodeficiency syndrome (AIDS), inflammatory bowel disease, or those receiving immunosuppressive therapy.…”